Kovitz Investment Group Partners LLC Purchases 1,670 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Kovitz Investment Group Partners LLC lifted its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 7.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 25,456 shares of the company’s stock after purchasing an additional 1,670 shares during the quarter. Kovitz Investment Group Partners LLC’s holdings in Takeda Pharmaceutical were worth $362,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in TAK. Millennium Management LLC boosted its position in shares of Takeda Pharmaceutical by 87.1% during the second quarter. Millennium Management LLC now owns 4,346,151 shares of the company’s stock worth $56,239,000 after purchasing an additional 2,023,707 shares in the last quarter. Cowen AND Company LLC bought a new stake in Takeda Pharmaceutical in the 2nd quarter valued at $6,866,000. Van ECK Associates Corp lifted its position in Takeda Pharmaceutical by 21.1% in the 2nd quarter. Van ECK Associates Corp now owns 2,040,829 shares of the company’s stock valued at $26,408,000 after acquiring an additional 356,069 shares in the last quarter. FMR LLC lifted its position in Takeda Pharmaceutical by 10.9% in the 3rd quarter. FMR LLC now owns 2,908,918 shares of the company’s stock valued at $41,365,000 after acquiring an additional 286,052 shares in the last quarter. Finally, Stifel Financial Corp lifted its position in Takeda Pharmaceutical by 103.9% in the 3rd quarter. Stifel Financial Corp now owns 440,666 shares of the company’s stock valued at $6,266,000 after acquiring an additional 224,594 shares in the last quarter. 9.17% of the stock is owned by institutional investors.

Takeda Pharmaceutical Trading Down 0.2 %

TAK opened at $13.42 on Friday. The stock has a market capitalization of $42.70 billion, a P/E ratio of 23.14, a P/E/G ratio of 0.26 and a beta of 0.51. Takeda Pharmaceutical Company Limited has a 12 month low of $12.57 and a 12 month high of $15.08. The firm’s fifty day simple moving average is $13.81 and its 200 day simple moving average is $13.87. The company has a current ratio of 1.28, a quick ratio of 0.77 and a debt-to-equity ratio of 0.64.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.